OGN vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 08, 2026

OGN

48.4
AI Score
VS
GSK Wins

GSK

48.7
AI Score

Investment Advisor Scores

OGN

48score
Recommendation
HOLD

GSK

49score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric OGN GSK Winner
Forward P/E 5.0891 10.0604 OGN
PEG Ratio 0 6.4902 Tie
Revenue Growth -1.7% 4.0% GSK
Earnings Growth -1.6% -22.8% OGN
Tradestie Score 48.4/100 48.7/100 GSK
Profit Margin 3.5% 13.0% GSK
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

OGN 1M: +0.9% · 3M: +1.2% GSK 1M: +9.4% · 3M: +0.3%

Current Technical Phase

OGN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 64.8 · Price: $13.89

GSK

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 54

RSI (14): 54.2 · Price: $50.60

Fundamentals Snapshot

Metric OGN GSK
Market Cap — —
Forward P/E 3.8 10.2
Trailing P/E 17.8 17.9
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.5% 0.7%
Operating Margin 0.2% 0.3%
EPS 0.78 2.87
Dividend Yield 0.01% 0.04%

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.